The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...
Faced with stress and brain fog, columnist Juliet Taylor thought that staying on top of things would keep her husband's ALS ...
Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...
Reflecting on past journal entries reminds columnist Kristin Neva that life as an ALS caregiver is always a mix of good and hard times.
A bipartisan team of congressional representatives is pushing for new legislation that aims to understand why veterans are at increased… ...
The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
With ALS, columnist Dagmar Munn says she must focus her mind and make deliberate choices when decision-making fatigue sets in.
The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback